Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
Should orlistat be avoided in patients with a history of kidney stones?
Related Questions
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?
Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
Are you more likely to recommend medical management for obesity instead of bariatric surgery in patients with preexisting hypothyroidism, given a recent study showing increased risks of complications?
What do you recommend to your patients to prevent muscle loss when prescribing a GLP-1 agonist for weight loss?
Why is it recommended to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after tirzepatide initiation but not with semaglutide?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
